Rekha Jhunjhunwala, as per the latest corporate shareholdings filed, publicly holds 19 stocks with an estimated net worth of over Rs. 11,866.8 crore. Some of the top holdings of the investor include Aptech, Crisil, Indian Hotels and Jubilant Pharmova and Fortis.

Top stock picks: The brokerage is bullish on private banks, insurance, select industrials, consumer discretionary, automobiles and telcos. Stocks in its portfolio include Maruti Suzuki, M&M, Sun Pharmaceutical, Fortis Healthcare, Bharti Airtel, HDFC Bank, ICICI Bank, Axis Bank and SBI Life Insurance.

“The near-term market construct is not favourable for equities. The rising Covid cases in the US, Korea, Brazil, and China is an area of concern. The situation is dire in China. This might impact market sentiments,” V K Vijayakumar, Chief Investment Strategist at Geojit Financial Services said.

Hardly any analyst ETMarkets spoke to sees Nifty slipping below the 18,000 mark in the next one year. The most optimistic of bulls are expecting the index to even zoom past the 20,000 mark. Global brokerage BofA Securities has built a base case Nifty target of 19,500 while Morgan Stanley sees the Sensex at 68,500 in 2023.

Valuation of Sensex is the highest among the emerging market peers, all of whom are trading at 0.9-1.7 times their 1-year forward price-to-book value, the brokerage said in a note

Prabhudas Lilladher is bullish on Fortis Healthcare has recommended buy rating on the stock with a target price of Rs 360 in its research report dated November 14, 2022.

“Once somebody has made an open offer, it has to get allowed to be completed. There is no stay order from Delhi High Court, there is nothing which prevents the open offer to go ahead. Why should the minority shareholders, rather the retail shareholders be allowed to suffer like this? Not allowing the open offer to proceed is completely against the interest of the retail shareholders.”

The IHH-Fortis deal has been stuck due to a legal battle between Japanese firm Daiichi Sankyo and former promoters of Fortis Malvinder Singh and his brother Shivinder

IHH Healthcare Managing Director and CEO Kelvin Loh had stated: "With the recent Supreme Court judgement ruling making clear that we have conducted our investment into Fortis in a fair and transparent manner, we are discussing with Sebi to move ahead with the offer."

Ambuja Cements is currently trading near its all-time high level which tells that the stock already is in strong momentum.

Among the exits, Jhunjhunwala and associates stake dropped below one per cent in Bilcare, Indiabulls Housing Finance and Autoline Industries as of September 30, 2022.

“The second quarter is a seasonally good quarter and there are variations from quarter to quarter and we would typically see that the second quarter is always slightly better. The third quarter is a quarter of the festivals and celebration and during this quarter, the occupancy levels may not go up so dramatically but eventually this is going towards 75% occupancy. Many of our hospitals are even currently working at about 75% occupancy.”

“The third quarter is a quarter of the festivals and celebration and during this quarter, the occupancy levels may not go up so dramatically but eventually this is going towards 75% occupancy. Many of our hospitals are even currently working at about 75% occupancy.”

Its consolidated revenue for the September quarter of FY23 stood at Rs 1,607 crore, up 9.9% as compared to Rs 1,462.5 crore in the corresponding period of the last fiscal. Its Q2FY23 hospital business revenues were at Rs 1,297 crore versus Rs 1,098.5 crore in Q2FY22.

It said that following the recent judgment of the Supreme Court, the special leave petition, the original contempt petition and the suo-moto contempt petition are disposed of.

The company reported a net profit of Rs 131 crore in the corresponding quarter of the previous year. The revenues rose 10% YoY to Rs 1607 crore in Q2FY23 compared to 1463 crore in Q2FY22.​The earnings before interest, tax, depreciation and amortization (EBITDA) stood at Rs 316 crore in Q2FY23, improving by 9% YoY. The EBITDA margin stood at 20%.

Shares of Ajanta Pharma (Rs 7 per share), GMM Pfaudler (Re 1 per share), Siyaram Silk (Rs 4 per share) and Nikko Parks (Re 0.4 per share) will trade ex-dividend. Shares of GPT Infraprojects will trade ex-bonus in respect of the bonus share issue in the ratio of 1:1.

“Capex as a theme is in vogue and among investors, there is definitely a liking for some of the companies where the overall performance has proved to be good and where the management is guiding for a better growth ahead. From that perspective, Cummins could be one stock to look at.”

“Capex as a theme is in vogue and among investors, there is definitely a liking for some of the companies where the overall performance has proved to be good and where the management is guiding for a better growth ahead. From that perspective, Cummins could be one stock to look at.”

Kelvin Loh, CEO, IHH Healthcare said IHH got several inbound queries, but the company was not interested in divesting its stake in Fortis as yet.

“The way Apollo has strategised the capital allocation policy and the value which they are creating in digital business is impressive. I would go with that company. Of course, there are other plays as well but when you like a sector, you go for the market leader and that generally works out pretty well.”

“For ITC, we are looking at about 19% kind of growth in the EBITDA and their non-cigarette business also will continue to do well – be it FMCG, paperboards and hotel business. In the cigarette business also, we are looking at a steady state kind of growth. We continue to have a positive bias there.”

On 14th December 2018, the Supreme Court had issued an interim order stalling the open offer by IHH. Post September 22 order, various legal experts feel that if a petition gets disposed off, all interim orders get merged with the final order or stand vacated unless mentioned otherwise.

On 14th December 2018, the Supreme Court had issued an interim order stalling the open offer by IHH. Post September 22 order, various legal experts feel that if a petition gets disposed off, all interim orders get merged with the final order or stand vacated unless mentioned otherwise.

On 14th December 2018, the Supreme Court had issued an interim order stalling the open offer by IHH. Post September 22 order, various legal experts feel that if a petition gets disposed off, all interim orders get merged with the final order or stand vacated unless mentioned otherwise.

On 14th December 2018, the Supreme Court had issued an interim order stalling the open offer by IHH. Post September 22 order, various legal experts feel that if a petition gets disposed off, all interim orders get merged with the final order or stand vacated unless mentioned otherwise.

“Even if we correct another 3% to 5% at the index level, people would be okay given that we have already gone up quite a lot from June onwards. We should just see to it that in this phase, we are able to navigate without much of a damage and look out for some opportunities where the growth visibility is high.”

The Supreme Court had last week ordered a forensic audit of the share sale of Fortis Healthcare to IHH Healthcare executed in 2018, in a contempt case filed by Japanese firm Daiichi Sankyo Company Ltd against the former promoters of Fortis, Singh brothers -- Malvinder and Shivinder, and others.

In the BSE500 index, 345 stocks settled in the red, whereas other 155 stocks posted gains for the week. Only eight stocks were able to rise 10 per cent or more, whereas the same number of stocks clocked double-digit cuts. Benchmark indices - BSE Sensex and Nifty 50 - dropped over a per cent each, while midcap and smallcap indices underperformed as they shed 2 per cent during the week. The BSE500 index was also down by more than a per cent.

Fortis Healthcare Ltd., incorporated in the year 1996, is a Mid Cap company (having a market cap of Rs 19466.60 Crore) operating in Hospitals & Allied Services sector.

Siddhartha Khemka, Head - Retail Research, Motilal Oswal Financial Services, said: “Indian markets again showed resilience in the face of global weakness after the US Fed sounded more hawkish in its future action. Nifty opened a gap down but attempted to recover twice during the day, to finally close with a loss of 86 points at 17,630”.

“From a business and growth perspective, both the Fortis businesses look pretty solid from a medium-term perspective. There are reasonably good growth drivers and to that extent, I will recommend it to investors to use this dip as more of a buying opportunity from our end.”

Shares of Fortis Healthcare plunged 16 per cent to Rs 263 on Thursday. The had stock ended the previous session at Rs 311.20 on BSE.

Fortis Healthcare Ltd. key Products/Revenue Segments include HealthCare Services, Other Operating Revenue, Lease Rentals, Pharmaceuticals and Export Incentives for the year ending 31-Mar-2022.

The stock is trading near its breakout point, placed at Rs 580. The key technical indicators are positively poised on long-term as well as medium-term timeframe charts, while its short-term indicators tested the overbought zone and may reverse.

Stocks that were in focus included names like Fortis Healthcare, which closed with gains of nearly 6 per cent, Allcargo Logistics gained more than 5 per cent, and Ambuja Cements ended with gains of nearly 8 per cent.

Regardless of age, a healthy heart is key to overall good health.

Fatehi was also summoned by the Central agency in October last year.

World Health Organization chief scientist Soumya Swaminathan said post-Covid, countries needed to prepare for large increases in cardiovascular, neurological and mental health disorders.

The summons came after the ED's latest charge sheet said the actress enjoyed valuables given by 'conman' Sukesh.

Additional Sessions Judge Praveen Singh on Wedneday took cognizance of the second supplementary charge sheet filed by the Enforcement Directorate(ED) in the Rs 200 crore money laundering case, and asked Fernandez to appear before the court on September 26.

Rupak De, Senior Technical Analyst at LKP Securities, said the momentum oscillator RSI is in a bearish crossover and falling towards the oversold zone. “The short-term trend, at the juncture, looks weak on the lower end, and the index may drift down towards 17,000-16,950 over the short term. On the higher end, resistance is visible at 17,500,” he said.

India's drug pricing authority has brought two key anti-diabetic drugs - Sitagliptin-Metformin combination and Linagliptin-Metformin combination - under price control. For a 2.5 mg Linagliptin-metformin tablet, the price has been fixed at 16.17, and for the same combination in 5 mg strength, the price will be 25.33 per tablet.

Last week, a joint India-UAE healthcare delegation visited Tanzania, recipient of India's biggest line of credit in Africa, to explore investment opportunities and meet senior government officials. The objective of the visit was to identify specific projects for collaboration with government and private healthcare providers in Tanzania.